NCT01056783View on ClinicalTrials.gov

Proof of Concept Study of OC000459 in Eosinophilic Esophagitis

PHASE2CompletedINTERVENTIONAL

Enrollment

26

Participants

Timeline

Start Date

August 31, 2010

Primary Completion Date

June 30, 2011

Study Completion Date

June 30, 2011

Conditions

Eosinophilic Esophagitis

Interventions

DRUG

OC000459

OC000459 100mg, twice daily, tablet

DRUG

Placebo

Placebo tablets to match OC000459 tablets, twice daily

Trial Locations (1)

CH-4600

Swiss EoE Research Group, Olten

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Oxagen Ltd

INDUSTRY